MX363946B - Anticuerpos humanos anti-cd27, metodos, y usos. - Google Patents

Anticuerpos humanos anti-cd27, metodos, y usos.

Info

Publication number
MX363946B
MX363946B MX2014011100A MX2014011100A MX363946B MX 363946 B MX363946 B MX 363946B MX 2014011100 A MX2014011100 A MX 2014011100A MX 2014011100 A MX2014011100 A MX 2014011100A MX 363946 B MX363946 B MX 363946B
Authority
MX
Mexico
Prior art keywords
antibodies
methods
cell proliferation
human anti
human
Prior art date
Application number
MX2014011100A
Other languages
English (en)
Other versions
MX2014011100A (es
Inventor
Raymond Sweet
Johan Fransson
Juan Carlos Almagro
Galina Obmolova
Thomas Malia
John Wheeler
John Chen
Natalie Fursov
Damon Hamel
Tatiana Ort
Michael Rycyzyn
Michael Scully
Alexey Teplyakov
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2014011100A publication Critical patent/MX2014011100A/es
Publication of MX363946B publication Critical patent/MX363946B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a los anticuerpos humanos immunoespecíficos para seres humanos CD27 son capaces de bloquear la unión de CD27 a su ligando CD70 y neutralizar la bioactividad de CD27 que incluye, pero sin limitarse a, señalización intracelular CD27, proliferación y activación de células T, proliferación y diferenciación de células B, formación de plasmablastos y alivio de las respuestas de anticuerpos, estimulación de células tumorales por CD70, y la producción de mediadores solubles de células T y B; los anticuerpos son útiles para diagnosticar o tratar la actividad de enfermedades y estados asociados con la actividad de CD27.
MX2014011100A 2012-03-15 2013-03-14 Anticuerpos humanos anti-cd27, metodos, y usos. MX363946B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611332P 2012-03-15 2012-03-15
PCT/US2013/031314 WO2013138586A1 (en) 2012-03-15 2013-03-14 Human anti-cd27 antibodies, methods and uses

Publications (2)

Publication Number Publication Date
MX2014011100A MX2014011100A (es) 2014-12-05
MX363946B true MX363946B (es) 2019-04-09

Family

ID=49157853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011100A MX363946B (es) 2012-03-15 2013-03-14 Anticuerpos humanos anti-cd27, metodos, y usos.

Country Status (28)

Country Link
US (5) US9102737B2 (es)
EP (1) EP2825200A4 (es)
JP (1) JP6487839B2 (es)
KR (1) KR102153374B1 (es)
CN (1) CN104284678B (es)
AR (1) AR090356A1 (es)
AU (1) AU2013232087B2 (es)
BR (2) BR112014022812A2 (es)
CA (1) CA2867299C (es)
CL (1) CL2014002416A1 (es)
CO (1) CO7071095A2 (es)
CR (1) CR20140415A (es)
EA (1) EA030828B1 (es)
EC (1) ECSP14018641A (es)
GT (1) GT201400193A (es)
HK (1) HK1206251A1 (es)
JO (1) JO3787B1 (es)
MX (1) MX363946B (es)
MY (1) MY175224A (es)
NZ (1) NZ629697A (es)
PE (1) PE20142242A1 (es)
PH (2) PH12014502011A1 (es)
SG (2) SG11201405437QA (es)
TW (2) TWI576354B (es)
UA (1) UA121844C2 (es)
UY (1) UY34680A (es)
WO (1) WO2013138586A1 (es)
ZA (2) ZA201407440B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2796571C (en) 2010-04-13 2019-10-29 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
CN103596979B (zh) 2011-03-16 2018-01-26 阿尔金-X有限公司 针对cd70的抗体
WO2014140374A2 (en) * 2013-03-15 2014-09-18 Novo Nordisk A/S Monovalent cd27 antibodies
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
FR3025517B1 (fr) 2014-09-10 2016-12-23 Repropharm Ligands potentialisants de la bioactivite des gonadotrophines
US20180244792A1 (en) * 2015-09-10 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
BR112018006251A2 (pt) 2015-09-30 2018-10-16 Janssen Biotech Inc anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
WO2017068192A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain cd27-receptor agonist proteins
WO2017117384A1 (en) 2015-12-31 2017-07-06 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
JOP20190055A1 (ar) * 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3524624A4 (en) * 2016-09-29 2020-06-17 Jiangsu Hengrui Medicine Co., Ltd. ANTI-CD27 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF, AND ITS MEDICAL USE
MX2019007404A (es) * 2016-12-23 2019-09-27 Macrogenics Inc Moleculas de union a adam9 y metodos de uso de las mismas.
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CA3062506A1 (en) 2017-05-12 2019-05-23 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
KR20200015921A (ko) * 2017-07-03 2020-02-13 재단법인 생물기술개발중심 항-vegfr 항체 및 이의 사용
WO2019037131A1 (zh) * 2017-08-25 2019-02-28 深圳市博奥康生物科技有限公司 一种cd27真核表达载体的构建及其高表达细胞株的制备
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
JP7359390B2 (ja) * 2018-02-09 2023-10-11 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
CA3094005A1 (en) * 2018-03-28 2019-10-03 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd27 antibody, antigen-binding fragment thereof and medical use thereof
WO2019195452A1 (en) * 2018-04-04 2019-10-10 Bristol-Myers Squibb Company Anti-cd27 antibodies and uses thereof
WO2019196117A1 (en) * 2018-04-13 2019-10-17 Dingfu Biotarget Co., Ltd. Anti-cd27 antibodies and use thereof
AU2019256383A1 (en) * 2018-04-17 2020-11-26 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
KR20210008502A (ko) 2018-05-11 2021-01-22 크리스퍼 테라퓨틱스 아게 암을 치료하기 위한 방법 및 조성물
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
US20220016168A1 (en) 2018-12-11 2022-01-20 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
TW202038958A (zh) 2018-12-18 2020-11-01 比利時商阿根思公司 Ｃｄ７０組合治療
US20220144961A1 (en) * 2019-03-11 2022-05-12 Xyence Therapeutics, Inc. Cd27-binding antibodies and uses thereof
CA3138633A1 (en) 2019-04-30 2020-11-05 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP2022532837A (ja) 2019-05-24 2022-07-20 エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド 抗ｃｓｆ１ｒ抗体、ｉｌ１０融合タンパク質、及びそれらの使用
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
CN112646029B (zh) * 2020-12-30 2022-07-29 深圳清华大学研究院 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CN116120451A (zh) * 2021-06-17 2023-05-16 南京蓝盾生物科技有限公司 抗cd70内化的抗体、抗体偶联物及其应用
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218525B1 (en) 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
KR100249937B1 (ko) 1991-04-25 2000-04-01 나가야마 오사무 인간 인터루킨-6 수용체에 대한 재구성 인간 항체
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
WO2001058953A2 (en) 2000-02-11 2001-08-16 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US6982361B1 (en) 2000-02-25 2006-01-03 The Regents Of The University Of California Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
EP1436329A4 (en) 2001-09-20 2005-04-27 Alexion Pharma Inc ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING FOCUSED ANTIBODIES
AU2003210266A1 (en) 2002-02-14 2003-09-04 Bioinvent International Ab Treatment, diagnosis and imaging of disease
US20060228710A1 (en) 2003-02-14 2006-10-12 Morris David W Novel therapeutic targets in cancer
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
AU2006252733A1 (en) 2005-06-02 2006-12-07 Astrazeneca Ab Antibodies directed to CD20 and uses thereof
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
EP2090320A1 (en) 2008-02-15 2009-08-19 Helmholtz-Zentrum für Infektionsforschung GmbH Ligands of the Natural Killer (NK) cell surface marker CD27 and therapeutic uses thereof
US9023999B2 (en) 2008-06-30 2015-05-05 Kyowa Hakko Kirin Co., Ltd Anti-CD27 antibody
ES2705015T3 (es) * 2009-12-29 2019-03-21 Kyowa Hakko Kirin Co Ltd Anticuerpo anti-CD27
CA2796571C (en) 2010-04-13 2019-10-29 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
AU2011275749C1 (en) * 2010-07-09 2015-09-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to CD27

Also Published As

Publication number Publication date
UA121844C2 (uk) 2020-08-10
SG11201405437QA (en) 2014-10-30
US20130243795A1 (en) 2013-09-19
WO2013138586A1 (en) 2013-09-19
ZA201500887B (en) 2016-01-27
UY34680A (es) 2013-09-30
MX2014011100A (es) 2014-12-05
JP6487839B2 (ja) 2019-03-20
PH12017501908A1 (en) 2018-10-01
US9102737B2 (en) 2015-08-11
TWI576354B (zh) 2017-04-01
BR122020002414B1 (pt) 2022-03-03
EA201491700A1 (ru) 2015-02-27
AR090356A1 (es) 2014-11-05
CO7071095A2 (es) 2014-09-30
CN104284678A (zh) 2015-01-14
HK1206251A1 (en) 2016-01-08
US20150299330A1 (en) 2015-10-22
AU2013232087B2 (en) 2018-02-08
PE20142242A1 (es) 2015-01-08
US20200277393A1 (en) 2020-09-03
CR20140415A (es) 2014-11-18
ECSP14018641A (es) 2018-10-31
NZ629697A (en) 2017-01-27
CA2867299A1 (en) 2013-09-19
EP2825200A4 (en) 2015-08-26
PH12014502011B1 (en) 2014-11-24
AU2013232087A1 (en) 2014-09-25
CA2867299C (en) 2019-08-27
CL2014002416A1 (es) 2015-01-16
EA030828B1 (ru) 2018-10-31
SG10201710574UA (en) 2018-02-27
TW201730214A (zh) 2017-09-01
KR20140133940A (ko) 2014-11-20
US11732050B2 (en) 2023-08-22
US10689453B2 (en) 2020-06-23
JO3787B1 (ar) 2021-01-31
BR112014022812A2 (pt) 2017-07-18
PH12017501908B1 (en) 2018-10-01
KR102153374B1 (ko) 2020-09-10
PH12014502011A1 (en) 2014-11-24
TW201345922A (zh) 2013-11-16
US10301392B2 (en) 2019-05-28
GT201400193A (es) 2017-06-14
US9683046B2 (en) 2017-06-20
EP2825200A1 (en) 2015-01-21
US20190248910A1 (en) 2019-08-15
US20170320957A1 (en) 2017-11-09
JP2015511965A (ja) 2015-04-23
MY175224A (en) 2020-06-16
ZA201407440B (en) 2016-07-27
CN104284678B (zh) 2018-04-24

Similar Documents

Publication Publication Date Title
PH12017501908A1 (en) Human anti-cd27 antibodies, methods and uses
EA033400B1 (ru) Антитело против cd3 и его применение
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
EA201690567A1 (ru) Антитела против pd1 и их применение в качестве терапевтических и диагностических средств
WO2011143318A3 (en) Anti-fgfr2 antibodies
MX2022001086A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
MX2020012426A (es) Anticuerpos anti-cd38.
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
EA201590870A1 (ru) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ
EP4309671A3 (en) Methods for increasing efficacy of folr1 cancer therapy
MX349096B (es) Anticuerpos anti-pd-l1 y sus usos.
MX2019006379A (es) Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
WO2015035250A3 (en) Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome
MX2015008117A (es) Anticuerpos anti-h7cr.
DK201300530A (en) Vaccine relating to Pancreas disease in fish
EA201500232A1 (ru) Три(гетеро)арилпиразолы и их применение
WO2014172653A3 (en) Anti-notch1 antibodies
陈若琨 et al. RRP22, a new neural tumor suppressor for gliomas
EA201992798A3 (ru) Антитела против pd1 и их применение в качестве терапевтических и диагностических средств
TN2013000265A1 (en) Anti-cd38 antibodies
NZ621320A (en) Anti-human xcr1 antibodies
MX355467B (es) Anticuerpos terapeuticos.

Legal Events

Date Code Title Description
FG Grant or registration